Research to pinpoint the biological underpinnings of what causes pain could help drug companies develop better pain medications and replace the health-care industry’s reliance on opioids.
The National Institutes of Health will soon invite scientists to apply for grants to discover and validate biological indicators, or biomarkers, to show that a response to the pain treatment has occurred. If successful, these biomarkers could improve clinical trials and potentially lead to better therapies for the 25 million Americans who are suffering from chronic pain.
“The lack of biomarkers has hampered research, particularly in drug development. We have very few, really ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.